PCSK9 Antikörper (C-Term)

Produktnummer ABIN3032340

Produktdetails anti-PCSK9 Antikörper

Target: PCSK9 (Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))

Bindungsspezifität: C-Term

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser PCSK9 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA

Aufreinigung: Antigen affinity purified

Immunogen: This PCSK9 antibody was produced from a rabbit immunized with a KLH conjugated synthetic peptide between 654-688 amino acids from the C-terminal region of human PCSK9.

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: Titration of the PCSK9 antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 1:1000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: In 1X PBS pH 7.4 with 0.09 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Aliquot the PCSK9 antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

Details zu PCSK9

Target: PCSK9 (Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))

Andere Bezeichnung: PCSK9 (PCSK9 Produkte)

Synonyme: FH3 antikoerper, HCHOLA3 antikoerper, LDLCQ1 antikoerper, NARC-1 antikoerper, NARC1 antikoerper, PC9 antikoerper, AI415265 antikoerper, AI747682 antikoerper, Narc1 antikoerper, proprotein convertase subtilisin/kexin type 9 antikoerper, proprotein convertase subtilisin/kexin type 9 L homeolog antikoerper, PCSK9 antikoerper, pcsk9.L antikoerper, pcsk9 antikoerper, Pcsk9 antikoerper

Hintergrund: Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.

UniProt: Q8NBP7